Direkt zum Inhalt
Merck
  • Metyrapone alleviates deleterious effects of maternal food restriction on lung development and growth of rat offspring.

Metyrapone alleviates deleterious effects of maternal food restriction on lung development and growth of rat offspring.

Reproductive sciences (Thousand Oaks, Calif.) (2014-06-12)
David S Paek, Reiko Sakurai, Aditi Saraswat, Yishi Li, Omid Khorram, John S Torday, Virender K Rehan
ZUSAMMENFASSUNG

Maternal food restriction (MFR) causes intrauterine growth restriction, a known risk factor for developing chronic lung disease. However, it is unknown whether this negative outcome is gender specific or preventable by blocking the MFR-induced hyperglucocorticoidism. Using a well-established rat model, we used metyrapone (MTP), an inhibitor of glucocorticoid synthesis, to study the MFR-induced lung changes on postnatal day (p) 21 in a gender-specific manner. From embryonic day 10 until delivery, pregnant dams were fed either an ad libitum diet or a 50% caloric restricted diet with or without MTP supplementation. Postnatally, the offspring were fed ad libitum from healthy dams until p21. Morphometric, Western blot, and immunohistochemical analysis of the lungs demonstrated that MTP mitigated the MFR-mediated decrease in alveolar count, decrease in adipogenic protein peroxisome proliferator-activated receptor γ, increase in myogenic proteins (fibronectin, α-smooth muscle actin, and calponin), increase in Wnt signaling intermediates (lymphoid enhancer-binding factor 1 and β-catenin), and increase in glucocorticoid receptor (GR) levels. The MFR-induced lung phenotype and the effects of MTP were similar in both genders. To elucidate the mechanism of MFR-induced shift of the adipogenic-to-myogenic phenotype, lung fibroblasts were used to independently study the effects of (1) nutrient restriction and (2) excess steroid exposure. Nutrient deprivation increased myogenic proteins, Wnt signaling intermediates, and GR, all changes blocked by protein supplementation. MTP also blocked, likely by normalizing nicotinamide adenine dinucleotide phosphate levels, the corticosterone-induced increase in myogenic proteins, but had no effect on GR levels. In summary, protein restriction and increased glucocorticoid levels appear to be the key players in MFR-induced lung disease, affecting both genders.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
DAPI, for nucleic acid staining
Sigma-Aldrich
Phenylmethansulfonylfluorid, ≥98.5% (GC)
Sigma-Aldrich
Ethylenglykol-bis(2-aminoethylether)-N,N,N′,N′-Tetraessigsäure, Molecular Biology, ≥97.0%
Sigma-Aldrich
Phenylmethansulfonylfluorid, ≥99.0% (T)
Sigma-Aldrich
Ethylenglykol-bis(2-aminoethylether)-N,N,N′,N′-Tetraessigsäure, ≥97.0%
Sigma-Aldrich
β-Nicotinamidadenin-Dinucleotidphosphat Hydrat
Sigma-Aldrich
DL-Glyceraldehyd-3-phosphat -Lösung, 45-55 mg/mL in H2O
Sigma-Aldrich
Ethylenglykol-bis(2-aminoethylether)-N,N,N′,N′-Tetraessigsäure, BioUltra, ≥99.0% (T)
Sigma-Aldrich
5,5-Diphenylhydantoin, ≥98%
Sigma-Aldrich
2,2′-Bichinolin-4,4′-dicarbonsäure Dinatriumsalz Dihydrat, ≥98% (HPLC)
Supelco
Phenytoin, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Ethylenglykol-bis(2-aminoethylether)-N,N,N′,N′-Tetraessigsäure, BioXtra, ≥97 .0%
Sigma-Aldrich
β-Nicotinamidadenin-Dinucleotidphosphat Natriumsalz, pkg of 5 mg (per vial)
Sigma-Aldrich
2-Methyl-1,2-di-3-Pyridyl-1-Propanon, 96%
USP
Phenytoin, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Metyrapon, ≥98% (HPLC), solid
Phenytoin, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
β-Nicotinamidadenin-Dinucleotidphosphat Natriumsalz, pkg of 10 mg (per vial)
Phenytoin für die Systemeignung, European Pharmacopoeia (EP) Reference Standard